• Boustead Securities

Boustead Securities Clients Graduate from OTC to Nasdaq: VirTra and Avalon Included in 2018 Uplist



VirTra, Inc. (NASDAQ: VTSI), (“VirTra”) and Avalon GloboCare Corp. (NASDAQ: AVCO) (“Avalon”), two client companies of Boustead Securities, LLC (Member: FINRA/SIPC) (“Boustead”), earned spots on the 2018 Uplist, highlighting fifty-eight companies that graduated from the OTC Markets to the NASDAQ or NYSE in 2018. VirTra made the list for its March 29, 2018 uplisting from the OTCQX to the NASDAQ Capital Market. Avalon uplisted from the OTCQB to the NASDAQ Capital Market on November 5, 2018.


VirTra, a global provider of training simulators for the law enforcement, military, educational and commercial markets, engaged Boustead as its NASDAQ sponsor and underwriter. VirTra produces realistic and highly effective virtual reality and simulator technology for global markets to train for judgmental use-of-force and de-escalation techniques.

After uplisting in the spring of 2018, VirTra’s third quarter 2018 operational and financial highlights report included the following accomplishments: VirTra launched nationally accredited coursework for law enforcement agencies to effectively teach, train, test, and sustain departmental training requirements.


“The engagement of Boustead Securities and the launch of our uplisting efforts are key events in the continued progress of VirTra”, stated Bob Ferris, Chairman and Chief Executive Office of VirTra.


Avalon, a leading global developer of cell-based technologies, similarly retained Boustead as its underwriter, financial advisor and NASDAQ sponsor for uplisting from the OTC Markets to a senior national exchange. Dr. David Jin, President and CEO of Avalon GloboCare noted that the benefits of a national exchange listing include increasing global visibility and access to significant partners, while enhancing shareholder value. Dr. Jin commented, “We are rapidly advancing a variety of cell-based therapies, particularly within the field of CAR-T cell therapy, while leveraging our proprietary exosome technology platform and aggressively expanding within the regenerative medicine market. We look forward to driving value for shareholders in the months and years ahead.”


Avalon’s mission is to accelerate and develop innovative and transformative cell-based technologies. In choosing to uplist to NASDAQ, Avalon engaged Boustead because of the investment bank’s track record and extensive relationships with investors in both the U.S. and Asia and highly experienced and reputable executive team.


“Boustead is proud to have assisted both Avalon and VirTra to uplist to NASDAQ in 2018. We look forward to seeing the growth and progress that these companies can achieve in 2019 and beyond, with the momentum provided by increased access to public investors,” commented Keith Moore, CEO of Boustead Securities.


About VirTra VirTra (NASDAQ: VTSI) is a global provider of training simulators for the law enforcement, military, educational and commercial markets. VirTra’s patented technologies, software and scenarios provide intense training for de-escalation, judgmental use-of-force, marksmanship and related training that mimics real world situations. VirTra’s mission is to save and improve lives worldwide through realistic and highly-effective virtual reality and simulator technology. Learn more about VirTra at www.VirTra.com.


About Avalon Globocare Corp. Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, disruptive cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Learn more about Avalon at www.avalon-globocare.com.


About Boustead Securities, LLC Member: FINRA/SIPC Boustead Securities, LLC is an investment banking firm that advises clients on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions. Our core value proposition is our ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead's team moves quickly and provides a broad spectrum of sophisticated financial advice and services. For more information visit www.boustead1828.com.


Legal Disclaimer This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No money or other consideration is being solicited at this time with respect to such an offering, and if sent in response to these materials for such an offering, it will not be accepted. Past performance is not indicative of future results. All investors are encouraged to consult with their tax and legal advisors prior to investing. VirTra’s and Avalon’s experience may not be representative of other Boustead clients.


CONTACT: Boustead Securities, LLC:  Dan McClory, Head of Equity Capital Markets +1 (949) 502 4408 dan@boustead1828.com

1 view

6 Venture, Suite 395

Irvine, CA 92618 USA

Locate Us

+1.949.502.4408

info@boustead1828.com

  • White LinkedIn Icon
  • White Facebook Icon
For any general inquiries, please fill in the following contact form: